Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Pacira Pharmaceuticals ( (PCRX) ) has issued an announcement.
On January 28, 2025, Pacira BioSciences announced significant changes to its Board of Directors, including the resignation of Paul J. Hastings, the Chair, and Andreas Wicki, a board member. Laura Brege was appointed as the new Chair, aligning with the company’s ongoing board refreshment strategy. These changes, alongside the reclassification of board members and committee reassignments, are part of Pacira’s 5×30 growth strategy, aimed at driving innovation and creating value in the non-opioid pain management market. This appointment marks a continued transformation of the board, ensuring the company is well-positioned to execute its strategic plan and enhance shareholder value.
More about Pacira Pharmaceuticals
Pacira BioSciences, Inc. is a leading company committed to delivering innovative non-opioid pain therapies. The company offers three commercial-stage non-opioid treatments: EXPAREL, ZILRETTA, and iovera°. These products serve significant markets with high unmet needs, and Pacira is advancing the development of PCRX-201, a novel gene therapy for diseases like osteoarthritis.
YTD Price Performance: 42.01%
Average Trading Volume: 785,671
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $1.19B
For detailed information about PCRX stock, go to TipRanks’ Stock Analysis page.
